Skip to main content
Bright Minds Biosciences Inc. logo

Bright Minds Biosciences Inc. — Investor Relations & Filings

Ticker · DRUG ISIN · CA10919W4056 CSE Professional, scientific and technical activities
Open in API
Filings indexed 198 across all filing types
Latest filing 2025-11-07 Regulatory Filings
Country CA Canada
Listing CSE DRUG

About Bright Minds Biosciences Inc.

https://brightmindsbio.com/

Bright Minds Biosciences Inc. is a biotechnology company specializing in the development of innovative therapeutics for neurological and psychiatric disorders, including severe and life-altering diseases such as epilepsy and Prader-Willi Syndrome. The company's scientific approach centers on healing the central nervous system and brain through the precise regulation of serotonin. Utilizing a proprietary chemistry platform, Bright Minds develops highly selective serotonin receptor agonists, specifically 5-HT2A and 5-HT2C agonists, designed to exclude 5-HT2B activity. This focus aims to create the next generation of serotonin-based drugs to address major challenges in mental health and neurology.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release containing two distinct sections: an announcement of upcoming investor conference presentations and a notification regarding the grant of equity incentive awards (stock options) to directors, officers, and consultants. While it mentions investor events, it is not an investor presentation itself. The equity grant section describes the issuance of stock options, which falls under the category of share-related capital changes or incentive disclosures. Given the primary nature of the document as a general corporate announcement covering multiple topics (events and equity grants), it fits best under the 'Regulatory Filings' (RNS) category as a general corporate news release.
2025-11-07 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing that company executives will present at the 2025 Jefferies Global Healthcare Conference and provides webcast details. This is an announcement of an upcoming investor-facing presentation event, matching the “Investor Presentation” category rather than a financial report, earnings release, or routine regulatory filing.
2025-05-28 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing featured speakers and event details for a virtual R&D Day webcast. It does not contain financial results, governance changes, voting results, or any detailed investor presentation materials—rather, it is an announcement of an upcoming event. No specific filing category (e.g., earnings release, proxy statement, capital raise, etc.) matches this type of event notice, so it falls into the fallback category for miscellaneous regulatory/press announcements. Therefore, it should be classified as a general Regulatory Filing (RNS).
2025-05-20 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a detailed product summary / prospectus supplement for a new structured note issuance by RBC, describing terms, dates, interest rates, barriers, and scenarios. It is not an annual or interim report, nor earnings release, nor board/management update, nor legal or M&A filing. Rather, it constitutes a financing activity – a capital-raising prospectus offering notes. Therefore it best fits Capital/Financing Update (CAP).
2025-03-04 French
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing the expansion of the company’s Scientific Advisory Board and the grant of equity incentive awards to certain directors, officers, and consultants. It does not contain financial results, regulatory filings, or details of legal proceedings. It is a management-level announcement concerning board/advisory appointments and compensation-related awards. Therefore, it best fits the “Board/Management Information” category.
2025-03-04 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Notice and Access notification for Bright Minds Biosciences Inc.’s Annual General Meeting, providing instructions for accessing proxy materials, voting procedures, and details on the Information Circular and form of Proxy. It is a pre-meeting solicitation of votes, fitting the definition of Proxy Solicitation & Information Statement (materials sent to shareholders to provide information and request votes).
2025-02-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.